Pagoclone

Buy Pagoclone online

Description of the

Buy PagoclonePagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other better-known drugs such as the sleeping pill zopiclone. It belongs to a relatively newly developed class of drugs known as non-benzodiazepines, which have similar effects to the older group of benzodiazepines but have a completely different chemical structure.

Synthesis analysis

The synthesis of pagoclones involves the reaction of 2-amino-7-chloro-1,8-naphthyridine with phthalic anhydride, which leads to the corresponding phthalimide. A selective reduction of one of the imide carbonyl groups yields the corresponding alcohol.

Analysing chemical reactions

Pagoclone is a subtype-selective drug that mainly binds to the alpha2/alpha3 subtypes of the GABAA receptor. These receptors are responsible for the anxiolytic effect of this type of medication.

Analysing physical and chemical properties

Pagoclone is a small molecule with the chemical formula C23H22ClN3O2. The average weight of the molecule is 407.893 and the monoisotope weight is 407.14005467 Buy Pagoclone.

Scientific research applications

Anxiolytic properties for panic disorder

Pagoclone, a cyclopyrrolone, acts as a partial agonist at the γ-aminobutyric acid (GABA) A/benzodiazepine (BDZ) receptor. A study evaluating its efficacy as an anti-panic agent provided preliminary evidence of its anxiolytic properties without typical BDZ side effects such as sedation, tolerance and withdrawal. This suggests a possible use in the treatment of panic disorder (DSM-IV) (Sandford et al., 2001).

Neuropsychological performance

The effects of pagoclone on neuropsychological performance in healthy individuals were studied and showed transient and slight negative effects on learning and memory scores at higher doses. However, these changes were not significant and disappeared on the sixth day of use, indicating a lack of behavioural toxicity (Caveney et al., 2008).

Development in panic and anxiety disorders

Pagoclone is being developed for the treatment of panic and anxiety disorders. Indevus started Phase II/III trials in 1996 and Pfizer conducted a Phase III trial for the treatment of panic disorder in 2000, but discontinued development of the drug in 2002 (Bateson, 2003).

Treatment of persistent developmental stuttering

In an exploratory study, pagoclone was investigated for the treatment of persistent developmental stuttering. Pagoclone was found to be effective in reducing stuttering symptoms and was well tolerated, suggesting its potential as a pharmacological treatment for stuttering (Maguire et al., 2010).

Pharmacological effects in rats

A study in rats showed that the pharmacological effects of pagoclone, such as the anxiolytic effect, are probably mediated by its main metabolite, 5′-hydroxy-pagoclone. This finding is crucial for understanding its in vivo properties (Atack et al., 2006) Buy Pagoclone.